Skip to main content

Ellison Foundation Provides U of Washington $6M for Alzheimer's Research

NEW YORK (GenomeWeb) – The Ellison Foundation announced on Sunday a $6 million gift to the University of Washington Alzheimer's Disease Research Center to accelerate the drug discovery pipeline for the disease. 

UW will use the investment to carry out four tasks, including implementing exome sequencing to test patients' genes to determine their risk of developing AD. Also, researchers will use patient-derived stem cells to test potential therapeutics at the Quellos High-throughput Screening Core at UW Medicine. Additionally, UW plans to recruit a senior scientist to lead the clinical trials team, which will test drugs on human volunteers. Lastly, UW will test a new imaging tool called functional magnetic resonance imaging to detect physiological changes in the brain, which may be a prelude to dementia. 

"When we know more about the genetics behind Alzheimer's disease and more about the drugs that may work on our patients, we'll be able to move on to our second phase: drug testing in clinical trials," UW Medicine CEO Paul Ramsey said in a statement. 

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.